Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesTumoral Prostate Shows Different Expression Pattern of Somatostatin Receptor 2 (SSTR2) and Phosphotyrosine Phosphatase SHP-1 (PTPN6) According to Tumor Progression
Advances in Urology, 06/16/09
Cariaga-Martinez AE et al. - Somatostatin receptor 2 (SSTR2) and SHP-1 tyrosine phosphatase are two fundamental components on antiproliferative effect of somatostatin. Normal epithelial prostate cells express SHP-1 and SSTR2, but we report that the levels of expression were diminished or lost for two proteins in advanced prostate cancer with an inverse ratio between protein expression and Gleason grade of tumor.
Related Articles
Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study
Journal of Clinical Oncology, 11/03/09
Relevance Score: 69%
Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer
Cancer Immunology, Immunotherapy, 10/26/09
Relevance Score: 68%
Zinc and prostatic cancer
Current Opinion in Clinical Nutrition & Metabolic Care, 10/16/09
Relevance Score: 68%
Somatic Single Hits Inactivate the X-Linked Tumor Suppressor FOXP3 in the Prostate
Cancer Cell, 10/12/09
Relevance Score: 68%
Translocator Protein Blockade Reduces Prostate Tumor Growth
Clinical Cancer Research, 10/01/09
Relevance Score: 68%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: a pilot study
Journal of Cancer Research & Clinical Oncology, 12/04/09
Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus
The Prostate, 12/04/09
DNA repair gene polymorphisms and prostate cancer risk in South Australia--results of a pilot study
Urologic Oncology: Seminars and Original Investigations, 12/03/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09
Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature
European Urology, 12/04/09
Article Search
Sponsor